SWEDENCARE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.65 SEK | +0.53% |
|
+3.00% | -7.07% |
| 04-25 | Swedencare AB Approves Dividend for the Year 2023, Payable on May 3, 2024 | CI |
| 04-25 | Transcript : Swedencare AB, Q1 2024 Earnings Call, Apr 25, 2024 |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an expected P/E ratio at 39.47 and 26.22 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 3.76 times the sales for the current fiscal year, the company turns out to be overvalued.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -7.07% | 832M | D+ | ||
| -15.35% | 76.34B | B+ | ||
| -9.19% | 6.67B | B- | ||
| +24.75% | 3.7B | B- | ||
| -1.11% | 3.21B | B- | ||
| +6.08% | 1.52B | - | ||
| -15.13% | 1.37B | B | ||
| -25.63% | 1.24B | C- | ||
| -7.62% | 1.21B | - | ||
| -10.84% | 1.17B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SECARE Stock
- Ratings Swedencare AB
